PCAS 
By 2013 RESULTS
Longjumeau, February 20, 2014
| 2012 | 2013 | ||||||||||
| In millions of euros | |||||||||||
| Net sales | 171,1 | 164,9 | |||||||||
| including Pharmaceutical Synthesis | 109,8 | 107,7 | |||||||||
| Including Fine Speciality Chemicals | 61,4 | 57,2 | |||||||||
| EBITDA (*) | 22,9 | 17,8 | |||||||||
| EBITDA margin | 13,4% | 10,8% | |||||||||
| Current Operating Income (*) | 12,3 | 8,3 | |||||||||
| dont Synthèse Pharmaceutique | 11,1 | 10,7 | |||||||||
| Other Operating income and expense | -1,9 | -1,4 | |||||||||
| Financial Result | -3,1 | -2,6 | |||||||||
| Taxes | -1,0 | -0,7 | |||||||||
| Share of profit/loss of associates | -0,3 | -0,1 | |||||||||
| Net Result from continuing operations | 6,1 | 3,5 | |||||||||
| Net Result on discontinued operation (**) | -3,1 | 0,0 | |||||||||
| Total Net Result | 3,0 | 3,5 | |||||||||
| Equity (***) | 71,1 | 78,3 | |||||||||
| Net debt | 52,5 | 47,0 | |||||||||
| Gearing | 0,74 | 0,60 | |||||||||
| Net asset (attributable to the Group) per share | 5,26 | 5,69 | |||||||||
| (*) of which research tax credit (CIR): 2.9 M? in 2013 and 2012. | |||||||||||
| (**) corresponding to SBS in 2012 whose sale was completed March 20, 2013. | |||||||||||
| (***) Including the impact of the new requirements of IAS 19 Employee Benefits for an estimated amount of - 1.2 M? | |||||||||||
| (net of deferred tax assets). | |||||||||||
| Audit procedures have been performed and auditor's report is in progress of being issued. | |||||||||||
The consolidated sales of the PCAS Group were down 3.6 % in 2013 compared to 2012.
Pharmaceutical Synthesis
Pharmaceutical Synthesis activities, affected by the planned slowdown of a contract, posted a slight fall (1.9%) in 2013 compared to 2012, whereas the patented molecule activity showed very satisfactory growth throughout the year 2013, while the generics activity slowed down in the fourth quarter of 2013.
Fine Specialty Chemicals
Fine Specialty Chemicals activities posted a 6.8% fall in 2013 compared to 2012, reflecting shrinking demand more particularly on European markets regarding the new technology segments, whereas Performance Chemicals and Fragrance-Flavors-Cosmetics activities showed continued growth in 2013.
Consequently, the Current Operating Income fell to 8.3 million euros in 2013 as against 12.3 million euros in 2012.
Net income totaled 3.5 million euros in 2013 as against 3.0 million euros in 2012.
Net debt also improved, falling to 47.0 million euros at 31 December 2013 compared to 52.5 million euros at 31 December 2012.
Productivity improvement measures and trade efforts aimed at achieving selective growth in sales, based more particularly on the development of proprietary products and technologies, should help improve the Group's economic performance in 2014. Meanwhile, efforts will continue to be made in favor of strategic projects with strong economical prospects, including the Protéus projects in the field of biotechnologies or even Enersens, which is developing a silica aerogel that has exceptional thermal insulation properties.
Next date: 2014 Shareholder's Meeting,
at 10 a.m. on April 23, 2014 in Longjumeau
About PCAS:
Financial reporting: Vincent Touraille - Eric Moissenot +33 (0)1 69 09 77 85 | www.pcas.com:
http://www.pcas.com/
http://hugin.info/143512/R/1763611/597709.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
